Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry

Peter A. Kaufman, Sara A. Hurvitz, Joyce O’Shaughnessy, Ginny Mason, Denise A. Yardley, Adam M. Brufsky, Hope S. Rugo, Melody Cobleigh, Sandra M. Swain, Debu Tripathy, Anne Morris, Vincent Antao, Haocheng Li, Mohammad Jahanzeb

Research output: Contribution to journalArticlepeer-review


Background: Systemic Therapies for HER2-Positive Metastatic Breast Cancer Study (SystHERs, NCT01615068) was a prospective, observational disease registry designed to identify treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer (MBC) in real-world treatment settings. Methods: SystHERs enrolled patients aged ≥ 18 years with recently diagnosed HER2-positive MBC. Treatment regimens and clinical management were determined by the treating physician. In this analysis, patients were compared descriptively by first-line treatment, age, or race. Multivariate logistic regression was used to examine the associations between baseline variables and treatment selections. Clinical outcomes were assessed in patients treated with trastuzumab (Herceptin [H]) + pertuzumab (Perjeta [P]). Results: Patients were enrolled from June 2012 to June 2016. As of February 22, 2018, 948 patients from 135 US treatment sites had received first-line treatment, including HP (n = 711), H without P (n = 175), or no H (n = 62) (with or without chemotherapy and/or hormonal therapy). Overall, 68.7% received HP + taxane and 9.3% received H without P + taxane. Patients aged < 50 years received HP (versus H without P) more commonly than those ≥ 70 years (odds ratio 4.20; 95% CI, 1.62–10.89). Chemotherapy was less common in patients ≥ 70 years (68.2%) versus those < 50 years (88.0%) or 50–69 years (87.4%). Patients treated with HP had median overall survival of 53.8 months and median progression-free survival of 15.8 months. Conclusions: Our analysis of real-world data shows that most patients with HER2-positive MBC received first-line treatment with HP + taxane. However, older patients were less likely to receive dual HER2-targeted therapy and chemotherapy.

Original languageEnglish (US)
Pages (from-to)179-190
Number of pages12
JournalBreast cancer research and treatment
Issue number1
StatePublished - Jul 2021
Externally publishedYes


  • Baseline characteristics
  • First-line treatment patterns
  • HER2-positive
  • Metastatic breast cancer
  • SystHERs

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry'. Together they form a unique fingerprint.

Cite this